Search clinical trials for: Ergoloid Mesylates

Total 1306 results

Alvotech Swiss AG
Iqvia Pty Ltd

Completed

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

Psoriasis

Australia, New Zealand
Eisai Inc.

Completed

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

HER2-normal

United States
Eisai Korea Inc.

Completed

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Locally Advanced or Metastatic Breast Cancer

Korea, Republic of
Goethe University

Completed

Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

ALL, Recurrent, Adult

Germany
Sarit Assouline
Novartis

Recruiting

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-Positive

Canada
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaborators

Completed

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Intracerebral Hemorrhage

United States, Canada
M.D. Anderson Cancer Center
BreakThrough Therapeutics

Completed

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Chronic Myeloid Leukemia | Minimal Residual Disease

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Myelogenous Leukemia, Chronic, Chronic Phase

United States
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Baim Institute for Clinical...

Completed

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) (KIA)

Asthma

United States
M.D. Anderson Cancer Center
Abiogen Pharma

Terminated

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Chronic Myelogenous Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Leukemia

United States
Herbert Hurwitz
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Stage IV Gastric Cancer | Recurrent Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer

Breast Cancer
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
Oncology Specialists, S.C.

Completed

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
M.D. Anderson Cancer Center
Novartis

Completed

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

Gastrointestinal Stromal Tumors

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eisai Inc.

Completed

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Ewing Sarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma | Relapsed/Refractory Rhabdomyosarcoma

United States
Taizhou EOC Pharma Co., Ltd.
Fountain Medical Development Co., Ltd.

Completed

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Rigshospitalet, Denmark
Danish Research Centre for Magnetic Resonance

Unknown

The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis (EPO-ProgMS)

Multiple Sclerosis (Primary or Secondary Progressive Phase).

Denmark
University of Texas Southwestern Medical Center

Completed

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

COVID-19 | Respiratory Viral Infection | Antiviral Treatment

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Melanoma | Skin Neoplasms

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease (PD)

Parkinson's Disease
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Gastrointestinal Stromal Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Prostate Cancer | Metastatic Cancer

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Austria, Germany, United States, United Kingdom
Peking University

Completed

Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

China
Technical University of Munich

Completed

Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer

Gastric Cancer

Germany
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Recurrent Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Adult Fibrosarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Novartis Pharmaceuticals

Terminated

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENEST)

Myelogenous Leukemia

United States, Germany, Belgium, Italy, Spain, Korea, Republic of, Brazil, Japan, Australia, Czech Republic
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Philadelphia Positive Chronic Myeloid Leukemia

United States, Germany, United Kingdom, France, Italy
Memorial Sloan Kettering Cancer Center

Active, not recruiting

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor (GIST)

United States
Dr. Jurjan Aman
Exvastat Ltd.; Simbec-Orion Group; KABS laboratories

Terminated

Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients (INVENT COVID)

Covid19 | Endothelial Dysfunction | Acute Respiratory Distress Syndrome | ARDS | Pulmonary Edema

Netherlands
M.D. Anderson Cancer Center
Novartis

Completed

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Prostate Cancer

United States
Amneal Pharmaceuticals, LLC
Accutest Research Laboratories (I) Pvt. Ltd.

Completed

Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

India
University of Southern California
Novartis

Completed

Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

Colorectal Cancer | Colon Cancer

United States
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
National Nutrition and Food Technology Institute

Unknown

The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

Non Alcoholic Steatohepatitis

Iran, Islamic Republic of
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Completed

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

Gastrointestinal Stromal Tumor

United States

Search clinical trials for: Ergoloid Mesylates

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations